Cited by

• Cardiac Amyloidosis: State-of-the-Art Review in Molecular Pathology.

  Salzillo C, Franco R, Ronchi A, Quaranta A, Marzullo A. Salzillo C, et al. Curr Issues Mol Biol. 2024 Oct 16;46(10):11519-11536. doi: 10.3390/cimb46100684. Curr Issues Mol Biol. 2024. PMID: 39451564 Free PMC article. Review.
• Automated Neural Architecture Search for Cardiac Amyloidosis Classification from [18F]-Florbetaben PET Images.

  Bargagna F, Zigrino D, De Santi LA, Genovesi D, Scipioni M, Favilli B, Vergaro G, Emdin M, Giorgetti A, Positano V, Santarelli MF. Bargagna F, et al. J Imaging Inform Med. 2024 Oct 2. doi: 10.1007/s10278-024-01275-8. Online ahead of print. J Imaging Inform Med. 2024. PMID: 39356368
• Prognostic Value of Serum Galectin-3 for Survival in Patients with Cardiac Light-Chain Amyloidosis.

  Yang X, Huang J, Zhang J, Li J, Tian Z. Yang X, et al. J Cardiovasc Dev Dis. 2024 Jun 29;11(7):202. doi: 10.3390/jcdd11070202. J Cardiovasc Dev Dis. 2024. PMID: 39057622 Free PMC article.
• A new staging system using right atrial strain in patients with immunoglobulin light-chain cardiac amyloidosis.

  Usuku H, Yamamoto E, Sueta D, Shinriki R, Oike F, Tabata N, Ishii M, Hanatani S, Hoshiyama T, Kanazawa H, Arima Y, Takashio S, Kawano Y, Oda S, Kawano H, Ueda M, Tsujita K. Usuku H, et al. ESC Heart Fail. 2024 Jun;11(3):1612-1624. doi: 10.1002/ehf2.14710. Epub 2024 Feb 23. ESC Heart Fail. 2024. PMID: 38400613 Free PMC article.
• Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study.

  Çavuşoğlu Y, Başarıcı İ, Tüfekçioğlu O, Özpelit E, Özdemir E, Sivrikoz İA, Altay H, Değertekin M, Dinçer İ, İkitimur B, Kahveci G, Bozkurt MF, Erkılıç M, Kaya GÇ, Beksaç M, Salihoğlu A, Tokgözoğlu L. Çavuşoğlu Y, et al. Front Cardiovasc Med. 2024 Jan 25;11:1299261. doi: 10.3389/fcvm.2024.1299261. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38333414 Free PMC article.